0001062993-24-013820.txt : 20240715 0001062993-24-013820.hdr.sgml : 20240715 20240715172925 ACCESSION NUMBER: 0001062993-24-013820 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240711 FILED AS OF DATE: 20240715 DATE AS OF CHANGE: 20240715 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rottinghaus Scott T. CENTRAL INDEX KEY: 0001942407 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35839 FILM NUMBER: 241118115 MAIL ADDRESS: STREET 1: C/O ENANTA PHARMACEUTICALS, INC. STREET 2: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-07-11 0001177648 ENANTA PHARMACEUTICALS INC ENTA 0001942407 Rottinghaus Scott T. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 0 1 0 0 Chief Medical Officer 1 Common Stock 2024-07-11 4 S 0 4299 15.07 D 23988 D Common Stock 2024-07-12 4 S 0 2271 15.04 D 21717 D Common Stock 2024-07-15 4 M 0 5375 8.99 A 27092 D Common Stock 2024-07-15 4 S 0 5375 17.08 D 21717 D Stock Option (Right to Buy) 8.99 2024-07-15 4 M 0 5375 0 D 2033-11-22 Common Stock 5375 80625 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.155, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.21, inclusive. The option, representing a right to purchase a total of 86,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023). The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2-4 above. /s/ Paul J. Mellett as attorney-in-fact 2024-07-15